In This Section      
Print This Page

Ciccarone Articles

Ciccarone Center Research

Journal

Circulation

Landmark Articles

Treatment of hypertension in the prevention and management of ischemic heart disease — a scientific statement from the AHA, ACCF, and ASH.
By: Rosendorf C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Gersh BJ, Gore JH, Levy D, Long JB, O’Gara PT, Oparil S, White WB.
Read on Pubmed
Coronary artery calcium testing: exploring the need for a randomized trial.
By: McEvoy JW, Blaha MJ.
Read on Pubmed
Coronary artery disease detected by coronary CT angiography is associated with intensification of preventive medical therapy and lower LDL cholesterol.
By: Hulten E, Bittencourt MS, Singh A, O’Leary D, Christman MP, Osmani W, Abbara S, Steigner M, Truong QA, Nasir K, Rybicki F, Klein J, Hainer J, Brady TJ, Hoffmann U, Ghoshhajra B, Hachamovitch R, Di Carli MF, Blankstein R.
Coronary computed tomography angiography (CCTA) may lead to increased use of prognostically beneficial therapies in patients identified as having extensive, non-obstructive CAD.
Read on Pubmed
Letter by Jones et al regarding article, “Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.”
By: Jones SR, Martin SS, Brinton EA.
Read on Pubmed
Two classic hemodynamic findings for hypertrophic cardiomyopathy.
By: Barth AS, Abraham T, Ndumele C, Zakaria S.
Read on Pubmed
Nonfatal outcomes in the primary prevention of atherosclerotic cardiovascular disease: is all-cause mortality really all that matters?
By: Czarny MJ, Martin SS, Kohli P, Metkus T, Blumenthal RS.
This article clearly shows that major nonfatal cardiovascular outcomes are very important to take into account when designing primary prevention guidelines.
Read on Pubmed
Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.
By: Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, Blankstein R, Budoff MJ, Greenland P, Folsom AR.
For the primary prevention of coronary heart disease (CHD), MESA participants with coronary artery calcium (CAC) ?100 were shown to have favorable risk/benefit estimations for aspirin use, while participants with zero CAC were estimated to receive net harm from aspirin.
Read on Pubmed
Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients.
By: Blaha MJ, Silverman MG, Budoff MJ.
Subclinical atherosclerosis testing with CAC is currently superior to any combination of risk factors and serum biomarkers.
Read on Pubmed
Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis Heart Trials.
By: Kim J, McEvoy JW, Nasir K, Budoff MJ, Arad Y, Blumenthal RS, Blaha MJ.
This analysis looks at the strengths and limitations of two large trials of statin therapy based on persons with an elevated hsCRP, CAC score, or both.
Read on Pubmed
Prognostic value of nonobstructive and obstructive coronary artery disease detected by coronary computed tomography angiography to identify cardiovascular events.
By: Bittencourt MS, Hulten E, Ghoshhajra B, D, Christman MP, Montana P, Truong QA, Steigner M, Murthy VL, Rybicki FJ, Nasir K, Gowdak LH, Hainer J, Brady TJ, Di Carli MF, Hoffmann U, Abbara S, Blankstein R.
Regardless of whether obstructive or nonobstructive disease is present, the extent of plaque detected by CCTA enhances risk assessment.
Read on Pubmed